Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Apixaban ODF (TAH3311) vs Eliquis in Healthy Volunteers
NCT05995119Phase 1Completed
- Sponsor
- TAHO Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in thromboembolism, Atrial fibrillation (AFib), deep vein thrombosis (DVT) and 1 more (4 arms), sponsored by TAHO Pharmaceuticals. Primary endpoints: Plasma Concentration (Cmax) of Apixaban under fasted condition, Area under the plasma concentration curve from time zero to last sampling time (AUC0-t) of Apixaban under fasted condition and 1 more. Started Dec 2022; status: completed.
02
Drugs
apixaban
03
Conditions
thromboembolismAtrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT05995119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05995119.